Nykode Therapeutics ASA

Regulatory Filings • Dec 19, 2025

Nykode Therapeutics to Present Interim Data from the VB-C-03 trial at the 10th International Congress on Innovative Approaches in Head & Neck Oncology (ICHNO) on March 20, 2026

Nykode Therapeutics to Present Interim Data from the VB-C-03 trial at the 10th International Congress on Innovative Approaches in Head & Neck Oncology (ICHNO) on March 20, 2026

Oslo, Norway, December 19, 2025 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced the oral presentation of interim data from the VB-C-03 trial at the 10th International Congress on Innovative Approaches in Head & Neck Oncology (ICHNO) on March 20, 2026.

The VB-C-03 trial is investigating abi-suva in combination with KEYTRUDA® (pembrolizumab) in 1st line unresectable recurrent or metastatic head and neck cancer patients (NCT06016920). Nykode is further advancing abi-suva development in 1st line head and neck cancer through the Abili-T phase 2 randomized controlled trial.

Presentation details:

Location: ICHNO 2026, Seville, Spain

Date: March 20, 2026

Time: 15:15-16:15 (CET)

The abstract is expected to be published on February 19, 2026.

Michael Engsig, Chief Executive Officer of Nykode, commented: “As previously announced, we look forward to providing further insight into the C-03 clinical data from 1st line head and neck cancer patients which supported our recently communicated strategy to further investigate abi-suva in this population with significant unmet needs.”

Furthermore, Michael Engsig, CEO and Agnete Fredriksen, CSO and Co-founder of Nykode Therapeutics will also be attending the 44th Annual J.P. Morgan Healthcare Conference and are available for 1:1 meetings.

About Nykode Therapeutics

Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies with a focus on the treatment of cancer and autoimmune diseases. Nykode’s modular immunotherapy technology specifically targets antigens to antigen presenting cells (APC), which have been shown to induce a broad, strong and long-lasting antigen specific immune response in cancer, which correlates with clinical responses.

Nykode’s lead product candidates are abi-suva, a therapeutic immunotherapy for the treatment of HPV16 induced malignancies which demonstrated favorable safety and efficacy results from its Phase 2 trial for the treatment of late-line r/m cervical cancer. Abi-suva is currently being further developed in head and neck cancer. VB10.NEO, an individualized cancer neoantigen immunotherapy, has been investigated in two trials with more than 10 different indications.

Nykode is also utilizing its APC-targeted technology to create an immune tolerance platform for the potential use in autoimmune disorders, organ transplant rejections, anti-drug antibody reactions and allergy.

Nykode Therapeutics’ shares are traded on the Oslo Stock Exchange (OSE: NYKD). Further information about Nykode Therapeutics can be found at http://www.nykode.com.

Forward-looking statements for Nykode Therapeutics

This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Contact for Nykode Therapeutics ASA:

IR@nykode.com

Nykode Therapeutics ASA

Oslo Science Park

Gaustadalléen 21

N-0349 Oslo, Norway